Product Information

ACITRETIN 25 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $3.6019 per EA under NDC 00378702393. Its NADAC has been published 537 times since May 11, 2016.

FDA first approved this application on Sep 10, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The Low Outlier badge above means this manufacturer's average price in the acitretin market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ACITRETIN 25 MG CAPSULE

acitretin
$3.6019per EA
Low Outlier

Strength

25 mg/1

NDC

00378702393

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

ACITRETIN

Approval Type

Generic (ANDA)

FDA Application

ANDA202148

FDA Approved

9/10/2015

TE Code

AB

On Market Since

3/10/2016

Pharmacological Classes

Retinoid
Retinoids

Price Statistics

The NADAC for ACITRETIN 25 MG CAPSULE has been published 537 times since May 11, 2016, and over the history we have for it it has declined 83.9%. The table below summarizes its recorded NADAC range and movement.

Current price$3.6019 per EA
All-time high$22.4276 (May 11, 2016)
All-time low$3.4171 (Apr 22, 2026)
52-week high$4.3092
52-week low$3.4171
Median price$9.6485
Average price$10.0299
Largest weekly change+62.9% (Oct 18, 2023)
Weeks tracked537
Tracking sinceMay 11, 2016

Price History

1W

-1.3%

1M

-1.3%

3M

+2.0%

6M

+2.3%

1Y

-16.4%

3Y

-13.2%

5Y

-69.1%

All

-83.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acitretin market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of ACITRETIN 25 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for ACITRETIN 25 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $3.6019 per EA (NDC 00378702393), effective Aug 19, 2026.

How has the price of ACITRETIN 25 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for ACITRETIN 25 MG CAPSULE has declined 83.9%. It has been tracked across 537 weekly CMS publications since May 11, 2016.

What are the highest and lowest recorded NADAC prices for ACITRETIN 25 MG CAPSULE?

Since May 11, 2016, the NADAC for ACITRETIN 25 MG CAPSULE has ranged from a low of $3.4171 (Apr 22, 2026) to a high of $22.4276 (May 11, 2016), with a median of $9.6485 per EA.

Are there cheaper alternatives to ACITRETIN 25 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of ACITRETIN 25 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ACITRETIN 25 MG CAPSULE?

ACITRETIN 25 MG CAPSULE (NDC 00378702393) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.